NW Bio Added To The MSCI Global MicroCap Index
Recognition To Enhance Immune Therapy Visibility In Global Financial Markets
BETHESDA, Md., June 3, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that NW Bio was added to the MSCI Global MicroCap Index as of the close of the stock market on Friday, May 31, 2013.
MSCI Inc. is a leading provider of investment decision support tools to investors worldwide, including asset managers, banks, hedge funds and pension funds. Among MSCI's key products are its worldwide indices used in assessing portfolio risks and performance. Headquartered in New York, MSCI has offices in all the major financial centers, and subscribing clients around the globe. Companies are moved both in and out of these key indices twice a year based on certain size and liquidity requirements.
"Coming on the heels of an exciting show at ASCO, with strong interest in the Company and its technology and clinical trials, as well as the high level of investor interest at recent conferences such as the Marcum MicroCap Conference, it is gratifying that our progress over the last year has been recognized through inclusion in this well-followed MSCI index," commented NW Bio CEO Linda Powers.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead program is a 312-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I/II trials in multiple other cancers. The Company has also conducted a Phase I/II trial with DCVax® for metastatic ovarian cancer together with the University of Pennsylvania.
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax® and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy. Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics
More by this Source
NW BIO AGAIN SETS FEUERSTEIN RECORD STRAIGHT
Apr 07, 2014, 08:15 ET
NW BIO REFUTES FURTHER FALSE AND MISLEADING CLAIMS BY FEUERSTEIN
Mar 28, 2014, 13:03 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.